<DOC>
	<DOC>NCT00436241</DOC>
	<brief_summary>This single arm study will assess the efficacy and safety of Xeloda in combination with oxaliplatin as first-line chemotherapy in patients with advanced and/or metastatic gastric cancer who have had no prior chemotherapy for advanced or metastatic disease. Eligible patients will receive Xeloda 1000mg/m2 po twice daily, D1-D10 every 2 weeks (10 days treatment followed by 4 days rest period) plus oxaliplatin 85 mg/m2/day iv, D1 every 2 weeks. The anticipated time on study treatment is until disease progression, and the target sample size is &lt;100 individuals.</brief_summary>
	<brief_title>A Study of Xeloda (Capecitabine) as First-Line Chemotherapy in Patients With Advanced or Metastatic Gastric Cancer.</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>adult patients, &gt;=18 years of age; gastric cancer with unresectable locally advanced and/or metastatic disease; &gt;=1 measurable lesion; ambulatory, with ECOG Performance Status &gt;=1. previous chemotherapy (except adjuvant or neoadjuvant treatment &gt;=6 months prior to enrollment); clinically significant cardiac disease or myocardial infarction within last 12 months; CNS metastases; history of other malignancy within last 5 years, except for cured basal cell cancer of the skin, or in situ cancer of the cervix.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>